Geode Capital Management LLC raised its position in shares of Masimo Co. (NASDAQ:MASI) by 5.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 611,628 shares of the medical equipment provider’s stock after purchasing an additional 29,170 shares during the period. Geode Capital Management LLC’s holdings in Masimo were worth $140,276,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Steward Partners Investment Advisory LLC raised its position in Masimo by 34.5% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 156 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 40 shares in the last quarter. Signaturefd LLC raised its position in Masimo by 8.6% during the first quarter. Signaturefd LLC now owns 545 shares of the medical equipment provider’s stock valued at $125,000 after purchasing an additional 43 shares in the last quarter. Commerce Bank raised its position in Masimo by 2.1% during the first quarter. Commerce Bank now owns 2,330 shares of the medical equipment provider’s stock valued at $535,000 after purchasing an additional 48 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Masimo by 0.3% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,963 shares of the medical equipment provider’s stock valued at $3,896,000 after purchasing an additional 49 shares in the last quarter. Finally, GWM Advisors LLC raised its position in Masimo by 2.9% during the first quarter. GWM Advisors LLC now owns 1,990 shares of the medical equipment provider’s stock valued at $457,000 after purchasing an additional 57 shares in the last quarter. Institutional investors and hedge funds own 80.99% of the company’s stock.
A number of analysts have weighed in on MASI shares. Robert W. Baird reaffirmed a “buy” rating and set a $310.00 target price on shares of Masimo in a research note on Thursday, April 29th. Piper Sandler decreased their target price on shares of Masimo from $310.00 to $295.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 24th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $284.80.
Shares of MASI opened at $238.49 on Wednesday. Masimo Co. has a 1 year low of $203.81 and a 1 year high of $284.86. The company has a market capitalization of $13.12 billion, a P/E ratio of 60.53 and a beta of 0.75. The business’s 50-day moving average is $224.98.
Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Sunday, April 25th. The medical equipment provider reported $0.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.02. Masimo had a return on equity of 14.95% and a net margin of 19.54%. The company had revenue of $299.04 million during the quarter, compared to the consensus estimate of $296.22 million. During the same period last year, the company earned $0.97 earnings per share. The firm’s revenue was up 10.9% compared to the same quarter last year. Sell-side analysts anticipate that Masimo Co. will post 3.83 EPS for the current fiscal year.
In other news, CFO Micah W. Young sold 2,087 shares of the firm’s stock in a transaction dated Thursday, April 8th. The stock was sold at an average price of $239.00, for a total transaction of $498,793.00. Following the completion of the transaction, the chief financial officer now directly owns 16,680 shares in the company, valued at $3,986,520. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.10% of the stock is owned by company insiders.
Masimo Profile
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: What Factors Can Affect Return on Equity?
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
